Welichem Begins Patient Enrollment for Phase IIb Trial of WBI-1001 Creams in Patients with Atopic Dermatitis
The study is being conducted at three centers across Canada. It is planned that 150 patients will be enrolled in the trial that is anticipated to be concluded in 6 to 9 months.
Most read news
Organizations
Other news from the department research and development
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.